Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

The FDA has approved a generic version of lenalidomide, a drug used to treat multiple myeloma and myelodysplastic syndromes, with availability set for Jan. 31, 2026.

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...

Cilta-cel enables sustained MRD negativity in patients with previously treated MM, according to results from the CARTITUDE-4 trial.

including lenalidomide and a proteasome inhibitor. The approval covers Sarclisa's use in combination with pomalidomide and dexamethasone (Pd). Regulators in China endorsed the drug based on ...